EnteroMedics, which designs and develops medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, filed terms with the SEC Friday for its upcoming IPO. The company plans to offer 5 million shares at a price range of $14 to $16 per share. JPMorgan and Morgan Stanley are the joint book runners on the deal.
